Neuromuscular Electrical Stimulation in the Critically Ill
Launched by BRUGMANN UNIVERSITY HOSPITAL · Sep 30, 2015
Trial Information
Current as of August 02, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admission in the ICU of the Brugmann Hospital (Unit 1020) with an intended ICU stay superior to 3 days
- • Aged over 18 years
- • Respiratory assistance needed (invasive and non-invasive ventilation, CPAP or Optiflow and PaO2(arterial oxygen pressure)/FiO2(fraction of inhaled oxygen)\<200mmHg)
- • SAPSII (Simplified Acute Physiology Score) between entre 35 et 70.
- Exclusion Criteria:
- Definitive exclusion criteria:
- • patients bearing a pacemaker or an AICD (automatic implantable cardioverter/defibrillator )
- • BMI superior to 35
- • serious neuromuscular pathologies or alterations in the inferior members that make both tights stimulation impossible
- • pregnant women
- • patients admitted from Friday evening to Sunday morning
- Temporary exclusion criteria:
- • Hemodynamic instability (even with filling up and amines: noradrenaline \> 0.5y/kg/min and/or dobutamine \>5y/kg/min and/or adrenaline ivc)
- • Extreme severity with suspicion of death within the first 24 h
- • PIC \> 20 cmH2O
- • Severe agitation (RASS \> +1)
- • Curare utilisation within the last 24h
About Brugmann University Hospital
Brugmann University Hospital is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative clinical research. As a prominent sponsor of clinical trials, the hospital integrates cutting-edge medical practices with rigorous scientific inquiry, focusing on a wide range of therapeutic areas. With a team of highly skilled researchers and clinicians, Brugmann University Hospital promotes collaboration across disciplines to enhance patient care and contribute to the development of new treatment modalities. Its state-of-the-art facilities and dedication to ethical research standards ensure the highest quality of clinical trial management and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Trial Officials
Jacques Devriendt, MD
Principal Investigator
CHU Brugmann
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials